Coronavirus Disease 2019-Associated Mucormycosis: Risk Factors and Mechanisms of Disease.
Date
2022-04-09Journal
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of AmericaPublisher
Oxford University PressType
Article
Metadata
Show full item recordAbstract
The severe surge of coronavirus disease 2019 (COVID-19) cases on the Indian subcontinent in early 2021 was marked by an unusually high number of COVID-19-associated mucormycosis (CAM) cases reported during this same period. This is significantly higher than predicted based on available data about prevalence and risk factors for this condition. This may be due to an unusual alignment of multiple risk factors for this condition. There is high background prevalence of mucormycosis in India likely from a high prevalence of risk factors, including undiagnosed or poorly controlled diabetes. COVID-19-induced immune dysregulation and immune suppression from steroid therapy increase the risk. The role of environmental exposure is unclear. System factors such as lack of access to healthcare during a pandemic may result in delayed diagnosis or suboptimal management with potentially poor outcomes. Here, we review currently identified risk factors and pathogenesis of CAM in a pandemic surge. © The Author(s) 2021.Rights/Terms
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.Identifier to cite or link to this item
http://hdl.handle.net/10713/18681ae974a485f413a2113503eed53cd6c53
10.1093/cid/ciab726
Scopus Count
Related articles
- Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India.
- Authors: Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I, Sharma R, Savio J, Sethuraman N, Madan S, Shastri P, Thangaraju D, Marak R, Tadepalli K, Savaj P, Sunavala A, Gupta N, Singhal T, Muthu V, Chakrabarti A, MucoCovi Network3.
- Issue date: 2021 Sep
- Coronavirus disease-associated mucormycosis (CAM): A case control study during the outbreak in India.
- Authors: Wasiq M, K R, Gn A
- Issue date: 2022 Apr
- Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World.
- Authors: Muthu V, Rudramurthy SM, Chakrabarti A, Agarwal R
- Issue date: 2021 Dec
- Cerebrovascular Involvement in Mucormycosis in COVID-19 Pandemic.
- Authors: Kulkarni R, Pujari SS, Gupta D, Ojha P, Dhamne M, Bolegave V, Dhonde P, Soni A, Adwani S, Diwan A, Duberkar D, Batra D, Deshpande R, Aurangabadkar K, Palasdeokar N
- Issue date: 2022 Feb
- Association of Serum Iron Studies in COVID Associated Mucormycosis with Stage of the Disease.
- Authors: Rao C, R M
- Issue date: 2022 Apr